Literature DB >> 25162603

Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.

Ernest A Kopecky1, Alison B Fleming1, Patrick K Noonan2, Ravi K Varanasi1, Michael Grima1, Said Saim1, Stephen P Mayock1.   

Abstract

OBJECTIVE: In vitro: To assess the effect of common crushing techniques on particle size reduction (PSR) and in vitro drug-release kinetics of oxycodone DETERx® (herein DETERx) and of a commercially available oxycodone extended-release (ER) tablet. In vivo: To evaluate the impact of the most effective manipulation method identified in the in vitro study and the effect of chewing on the pharmacokinetics (PK) of DETERx relative to oxycodone solution.
DESIGN: In vitro: Mechanical manipulation of dosage forms using common household utensils. In vivo: Open-label, randomized, active-controlled, crossover PK study.
SUBJECTS: In vivo: Forty-four healthy male and female volunteers.
METHODS: In vitro: DETERx capsule contents and marketed comparator tablets were subjected to manipulation (crushing) using 10 different household utensils. Particle size and dissolution analysis were conducted. In vivo: Subjects were randomly assigned to receive DETERx 40-mg capsules intact, crushed, or chewed or oxycodone solution. Serial blood samples were drawn for PK assessment.
RESULTS: In vitro: The utensils used to manipulate DETERx capsule contents were either ineffective in reducing the particle size or produced only a small change in the median particle size and dissolution rate relative to the marketed comparator. In vivo: DETERx intact capsules provided significantly lower Cmax and longer Tmax values than oxycodone solution. Manipulation of DETERx by crushing (using the most effective method established in vitro) or chewing resulted in bioequivalent plasma concentration-time profiles to the intact dosage form.
CONCLUSION: These mechanical manipulation and PK studies demonstrated that DETERx beads retained their ER properties after mechanical tampering and chewing by study subjects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25162603     DOI: 10.5055/jom.2014.0211

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  11 in total

Review 1.  Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Carmen Walter; Claudia Knothe; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 2.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

Review 3.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 4.  Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain.

Authors:  Jeff Gudin
Journal:  Pain Ther       Date:  2016-11-21

5.  Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.

Authors:  Ernest A Kopecky; Ben Vaughn; Scott Lagasse; Melinda O'Connor
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 3.923

6.  Response to Crudele et al. Commentary on Gudin et al. "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties".

Authors:  Jeff Gudin; Ernest A Kopecky; Alison B Fleming
Journal:  Pain Med       Date:  2017-05-01       Impact factor: 3.750

7.  Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®).

Authors:  Jody L Green; Rebekkah S Robbins; Taryn Dailey-Govoni; Stephen F Butler
Journal:  J Pain Res       Date:  2021-06-15       Impact factor: 3.133

8.  Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).

Authors:  Ernest A Kopecky; Alison B Fleming; Naama Levy-Cooperman; Melinda O'Connor; Edward M Sellers
Journal:  J Clin Pharmacol       Date:  2016-11-01       Impact factor: 3.126

9.  In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations.

Authors:  Stephen P Mayock; Said Saim; Alison B Fleming
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 3.580

10.  Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone.

Authors:  John Markman; Diana S Meske; Ernest A Kopecky; Ben Vaughn; Melinda L O'Connor; Steven D Passik
Journal:  J Pain Res       Date:  2018-09-26       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.